Turnstone Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Turnstone Biologics's estimated annual revenue is currently $29.1M per year.
- Turnstone Biologics received $41.4M in venture funding in November 2016.
- Turnstone Biologics's estimated revenue per employee is $193,750
- Turnstone Biologics's total funding is $132.7M.
- Turnstone Biologics has 150 Employees.
- Turnstone Biologics grew their employee count by 23% last year.
Turnstone Biologics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Turnstone Biologics?
Turnstone Biologics is a privately-held immuno-oncology company dedicated to delivering breakthrough viral immunotherapies to improve survival for patients with cancer. With an experienced leadership team passionate about helping people with cancer, comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing and commercialization, Turnstone Biologics is the sole company developing viral immunotherapies to drive benefit through simultaneous generation of a targeted immune response and modulation of the tumor environment. The company's engineered oncolytic Maraba virus, known as MG1, is the first therapeutic 2-in-1 approach to combine an oncolytic virus and an antigen-specific cancer vaccine. With its unprecedented dual-mechanism approach, MG1 kills cancer cells both locally and at metastatic sites throughout the body, and generates a durable immune response resulting in long-term memory to prevent recurrence. The company has developed a robust pipeline of new medicines for multiple solid tumors. The most advanced program, called Ad-MG1-MAGEA3, is being evaluated in patients with non-small cell lung cancer (NSCLC), breast cancer and esophageal cancer in two clinical trials. A second Maraba-based therapy designed for patients with human papillomavirus (HPV) positive tumors and multiple other viral immunotherapies are in development. Turnstone Biologics has entered into a research, option and license agreement with AbbVie for its next-generation viral immunotherapies. In 2017, the company was selected as a Fierce 15 winner - a designation signifying that it is considered one of the up-and-coming biotech companies expected to make big waves in the industry. Based in Ottawa, Ontario, and New York, Turnstone Biologics has raised approximately $50 million in venture capital financing since inception.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
Turnstone Biologics News
and Turnstone Biologics Corp. have named new general counsel recently, highlighting Law360's latest roundup of personnel moves in health care...
Turnstone Biologics Corp., a clinical-stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering...
Turnstone Biologics Announces Executive Leadership Appointments. Additions of Venkat Ramanan, Ph.D., as Chief Financial Officer and P. Joseph...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Turnstone Biologics Funding